{"id":"arb-dmx-200","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ARBs block angiotensin II type 1 receptors to lower blood pressure and reduce cardiovascular strain. DMX-200 is a proprietary drug delivery platform from UMC Utrecht that may improve bioavailability, tissue targeting, or sustained release of the ARB component. The combination aims to optimize cardiovascular outcomes while potentially minimizing systemic side effects through targeted delivery.","oneSentence":"ARB + DMX-200 combines an angiotensin II receptor blocker with DMX-200, a drug delivery technology designed to enhance therapeutic efficacy and potentially reduce adverse effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:59.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (presumed primary indication based on ARB class)"},{"name":"Cardiovascular protection in phase 3 development"}]},"trialDetails":[{"nctId":"NCT05183646","phase":"PHASE3","title":"A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB","status":"RECRUITING","sponsor":"Dimerix Bioscience Pty Ltd","startDate":"2022-05-30","conditions":"FSGS","enrollment":286},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05122182","phase":"PHASE2","title":"Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19","status":"TERMINATED","sponsor":"University of Sydney","startDate":"2022-01-07","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ARB + DMX-200","genericName":"ARB + DMX-200","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARB + DMX-200 combines an angiotensin II receptor blocker with DMX-200, a drug delivery technology designed to enhance therapeutic efficacy and potentially reduce adverse effects. Used for Hypertension (presumed primary indication based on ARB class), Cardiovascular protection in phase 3 development.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}